KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $307.0 million.

  • Royalty Pharma's Net Cash Flow rose 13769.2% to $307.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 18165.25%. This contributed to the annual value of $452.0 million for FY2024, which is 13663.78% up from last year.
  • As of Q3 2025, Royalty Pharma's Net Cash Flow stood at $307.0 million, which was up 13769.2% from -$455.8 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Net Cash Flow registered a high of $921.6 million during Q2 2024, and its lowest value of -$1.2 billion during Q3 2023.
  • For the 5-year period, Royalty Pharma's Net Cash Flow averaged around -$3.7 million, with its median value being $197.4 million (2023).
  • The largest annual percentage gain for Royalty Pharma's Net Cash Flow in the last 5 years was 37684.13% (2022), contrasted with its biggest fall of 26953.12% (2022).
  • Over the past 5 years, Royalty Pharma's Net Cash Flow (Quarter) stood at -$259.8 million in 2021, then soared by 376.84% to $719.1 million in 2022, then crashed by 163.89% to -$459.4 million in 2023, then surged by 95.42% to -$21.0 million in 2024, then surged by 1560.27% to $307.0 million in 2025.
  • Its Net Cash Flow was $307.0 million in Q3 2025, compared to -$455.8 million in Q2 2025 and $158.7 million in Q1 2025.